Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis (Q48322904)
Jump to navigation
Jump to search
scientific article published on 7 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis |
scientific article published on 7 January 2013 |
Statements
1 reference
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis (English)
1 reference
C Mamolo
1 reference
J Harness
1 reference
H Tan
1 reference
A Menter
1 reference
7 January 2013
1 reference
28
1 reference
2
1 reference
192-203
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference